| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/06/2002 | WO2002068617A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/06/2002 | WO2002068548A1 Use of erss-selective ligands for regulating fertility and compounds useful therefore |
| 09/06/2002 | WO2002068444A1 Ttk in diagnosis and as a therapeutic target in cancer |
| 09/06/2002 | WO2002068415A1 Pyrazole compounds useful as protein kinase inhibitors |
| 09/06/2002 | WO2002068395A1 Hiv inhibiting n-aminoimidazole derivatives |
| 09/06/2002 | WO2002068388A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 09/06/2002 | WO2002068387A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 09/06/2002 | WO2002068058A2 Dapd combination therapy with imdph inhibitors such as ribavirin or mycophenolic acid |
| 09/06/2002 | WO2002068056A2 Combination comprising a 1,4-dioxonaphathalene compound and ribenoside |
| 09/06/2002 | WO2002068015A2 Modular infusion device and method |
| 09/06/2002 | WO2002067998A2 Devices and methods for the treatment of cancer |
| 09/06/2002 | WO2002067988A2 Use of natural egfr inhibitors to prevent side effects due to retinoid therapy, soaps, and other stimuli that activate the epidermal growth receptor |
| 09/06/2002 | WO2002067987A2 Combinations of a 5ht1 receptor agonist with an analgesic, and an anti-emetic and/or a gastroprokinetic agent |
| 09/06/2002 | WO2002067986A2 Symbiotic regenerative agent |
| 09/06/2002 | WO2002067980A1 Method for treating von willebrand's disease |
| 09/06/2002 | WO2002067974A1 Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis |
| 09/06/2002 | WO2002067968A2 14-3-3 binding molecules as sensitizers for anticancer therapies |
| 09/06/2002 | WO2002067951A2 Use of 5-substituted nucleosides and/or prodrugs thereof in the resistance-free treatment of infectious diseases |
| 09/06/2002 | WO2002067941A2 Combination comprising a signal transduction inhibitor and an epothilone derivative |
| 09/06/2002 | WO2002067928A2 Metronomic dosing of taxanes for inhibiting tumor growth |
| 09/06/2002 | WO2002067917A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 09/06/2002 | WO2002067916A2 Pharmaceutical salts |
| 09/06/2002 | WO2002067915A1 Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function |
| 09/06/2002 | WO2002067909A1 New method of bronchodilatory therapy |
| 09/06/2002 | WO2002067908A1 Novel dendritic polymers and their biomedical uses |
| 09/06/2002 | WO2002067902A2 Modulation of release from dry powder formulations |
| 09/06/2002 | WO2002067901A1 Fibrate-statin combinations with reduced fed-fasted effects |
| 09/06/2002 | WO2002067873A2 Method for suppressing reduction of elasticity of skin |
| 09/06/2002 | WO2002067870A2 Composition and method for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease |
| 09/06/2002 | WO2002067869A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 09/06/2002 | WO2002067864A2 Coenzyme q products exhibiting high dissolution qualities |
| 09/06/2002 | WO2002067853A2 A combination and method of treatment of hiv and viral diseases, vascular disease and cancer utilizing a cox-2 inhibitor and cystine |
| 09/06/2002 | WO2002067831A1 Composition for freshening nostrils and sinus cavities |
| 09/06/2002 | WO2002067764A2 Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation |
| 09/06/2002 | WO2002067760A2 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
| 09/06/2002 | WO2002067688A1 Noninvasive measurements of chemical substances |
| 09/06/2002 | WO2002067681A1 Restore cancer-suppressing functions to neoplastic cells through dna hypomethylation |
| 09/06/2002 | WO2002067651A2 Pharmaceutical salts |
| 09/06/2002 | WO2002053092A3 Methods employing and compositions containing plaque associated molecules for prevention and treatment of atherosclerosis |
| 09/06/2002 | WO2002047712A3 Peptide yy and peptide yy agonists for treatment of metabolic disorders |
| 09/06/2002 | WO2002046216A3 Human sprouty-4 polypeptide |
| 09/06/2002 | WO2002043716A3 Method for regulating prostate gland volume with insulin sensitizers |
| 09/06/2002 | WO2002043659A3 Composition containing statins and calcium for improved cardiovascular health |
| 09/06/2002 | WO2002041882A3 Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity |
| 09/06/2002 | WO2002039958A3 Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents |
| 09/06/2002 | WO2002039121A3 Methods for detecting the efficacy of anticancer treatments |
| 09/06/2002 | WO2002036771A3 Imaging, diagnosis and treatment of disease |
| 09/06/2002 | WO2002030405A3 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
| 09/06/2002 | WO2002024185A3 Topical analgesic compositions containing aliphatic polyamines and methods of using same |
| 09/06/2002 | WO2002019985A3 Methods for inhibiting decrease in transdermal drug flux by inhibition of pathway closure |
| 09/06/2002 | WO2002008449A3 Ho-1 suppressor as a diagnostic and prognostic test for dementing diseases |
| 09/06/2002 | WO2002005796A3 Use of a spla2 inhibitor for the treatment of sepsis |
| 09/06/2002 | WO2002002629A3 Grf2-binding proteins and applications thereof |
| 09/06/2002 | WO2002000687A3 Antimicrobial peptides and methods of use thereof |
| 09/06/2002 | WO2001085785A3 Ph domain-interacting protein |
| 09/06/2002 | WO2001058915A8 Human g-protein chemokine receptor (ccr5) hdgnr10 |
| 09/06/2002 | WO2001024792A9 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog |
| 09/06/2002 | WO2001018546A9 Screening for inhibitors of 'paired helical filaments' |
| 09/06/2002 | WO2001014581A9 Hdac4 and hdac5 in the regulation of cardiac gene expression |
| 09/06/2002 | WO2001012674A9 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 09/06/2002 | WO2001012236A9 Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| 09/06/2002 | CA2725635A1 Pharmaceutical salts of 6-dimethylaminomethyl-1-phenylcyclohexane compounds |
| 09/06/2002 | CA2617312A1 Noninvasive measurement of chemical substances |
| 09/06/2002 | CA2617004A1 Noninvasive measurements of chemical substances |
| 09/06/2002 | CA2477043A1 Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer |
| 09/06/2002 | CA2439299A1 Metronomic dosing of taxanes |
| 09/06/2002 | CA2439261A1 Composition and method for preventing and treating sinusoidal obstruction syndrome and radiation-induced liver disease |
| 09/06/2002 | CA2439119A1 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 09/06/2002 | CA2439053A1 Hiv inhibiting n-aminoimidazole derivatives |
| 09/06/2002 | CA2438784A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 09/06/2002 | CA2438761A1 Method for treating von willebrand's disease |
| 09/06/2002 | CA2438630A1 Composition for freshening nostrils and sinus cavities |
| 09/06/2002 | CA2438268A1 Modulation of release from dry powder formulations |
| 09/06/2002 | CA2438193A1 Novel dendritic polymers and their biomedical uses |
| 09/06/2002 | CA2437530A1 Symbiotic regenerative agent |
| 09/06/2002 | CA2435739A1 Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function |
| 09/06/2002 | CA2432287A1 Dapd combination therapy with inosine monophosphate dehydrogenase inhibitor |
| 09/06/2002 | CA2432029A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/06/2002 | CA2430702A1 Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus |
| 09/05/2002 | US20020124272 Diploid animal cell for use in the treatment of drug addiction, epilepsey, withdrawal syndrome and muscle spasm |
| 09/05/2002 | US20020123618 Nucleotide sequences coding polypeptide for use in the diagnosis, prevention and treatment of autoimmune, thyroid and grave's disease |
| 09/05/2002 | US20020123614 Modified polypeptides stabilized in a desired conformation and methods for producing same |
| 09/05/2002 | US20020123527 Administering a 2-hydroxy-4-oxo- or 4,6-dioxo-6-pheny-l or naphthyl- hex-2-enoic acid; viricides; AIDS/ARC |
| 09/05/2002 | US20020123521 Such as triiodothyroacetic acid, triiodopropionic acid, 4-(2,6-dibromo-4-(1H-tetrazol-5-ylmethyl)-phenoxy)-2-isopropyl-phenol, and 4-(4-hydroxymethyl-2,6-diiodophenoxy)-2-iodo-phenol |
| 09/05/2002 | US20020123514 Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor |
| 09/05/2002 | US20020123513 Administering indole-2-carboxylic amide derivatives of given formula |
| 09/05/2002 | US20020123512 Pharmaceutical composition |
| 09/05/2002 | US20020123510 Administering an NR2B subtype selective N-methyl-D-aspartate (NMDA) receptor antagonist with a thrombolytic agent for treating hypoxic or ischemic stroke |
| 09/05/2002 | US20020123500 CSAIDs.TM block cytokine production; use of a cytokine inhibitor for the treatment of chronic diseases which are caused by inappropriate angiogenesis, such as diabetic retinopathy, tumors, atherosclerosis and arthritis |
| 09/05/2002 | US20020123498 For inhibiting transport protein; therapy |
| 09/05/2002 | US20020123493 For therapy and prophylaxis of neuronal damage |
| 09/05/2002 | US20020123490 Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis |
| 09/05/2002 | US20020123489 Benzamidine derivatives |
| 09/05/2002 | US20020123485 For therapy of hypertension, cirrhosis and ascites |
| 09/05/2002 | US20020123476 For treating infectious diseases and genetic disorders through gene therapy and intracellular delivery of antisense oligonucleotides or other nucleic acid sequences |
| 09/05/2002 | US20020123469 Antiproliferative colchicine compositions and uses thereof |
| 09/05/2002 | US20020123461 Enhancement of GLP-2 activity |
| 09/05/2002 | US20020123120 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/05/2002 | US20020123119 Nucleotide sequences coding enzymatic polypeptide for use in screening bactericides and for treatment and prevention of infections |
| 09/05/2002 | US20020123047 dexB |